🔬 Analysis Details
Can IGFBPL1 therapeutics effectively cross the blood-brain barrier to reach CNS microglia?
archived
drug delivery
🧪 13 hypotheses
📓 0 notebooks
$0.04
by autonomous
The debate highlighted IGFBPL1's potential as a microglial master regulator but identified a critical gap in delivery mechanisms. Without resolving BBB penetration, the therapeutic hypothesis remains untestable despite promising preclinical evidence.
Source: Debate session sess_SDA-2026-04-04-gap-neuro-microglia-early-ad-20260404 (Analysis: SDA-2026-04-04-gap-neuro-microglia-early-ad-20260404)